| Revenue growth | 11.8% YoY growth; driven by India and Global Specialty business. |
|---|---|
| Margins | EBITDA margins down YoY at 29.3% due to lower Lenalidomide contribution. |
| Demand visibility | Strong chronic demand in India; expanding psoriatic arthritis market in U.S. |
| Management confidence | Balanced, though cautious regarding U.S. specialty execution and Ilumya slowdown. |
Growth
Revenue rose 11.8% YoY; India business led with 17.3% growth fueled by volume expansion.
Outlook
Expect Q4 FY27 Organon close; R&D spend to ramp up in H2 FY27.
Risks
U.S. Ilumya slowdown, rising R&D spend, and voluntary product recalls in India pose margin threats.
Last quarter's promises, checked
Delivered
- Guided FY27 high-single-digit revenue growth → Q2 +11.8% YoY, quarter only (= BEAT)
Partly delivered
- Guided Organon close Q4 FY27 → reaffirmed Q4 FY27, not yet due (= PARTIAL)
- Guided annual R&D 'met', no figure → H2 FY27 ramp flagged, unquantified (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: SUNPHARMA. Summary written with AI assistance from the document.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,777.70
- Market cap
- ₹4,26,530 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 35.3×Sector 45.9×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries Other Announcement
Sun Pharmaceutical Industries submitted the quarterly confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, as received from their RTA.